Come join others currently navigating treatment in our weekly Virtual Support Groups! See times and register here.

Kadcyla Continues to Improve Survival in HER2-Positive Early-Stage Breast Cancer

Kadcyla Continues to Improve Survival in HER2-Positive Early-Stage Breast Cancer

Dec 17, 2023 

More than eight years of follow-up from the KATHERINE trial showed the continued survival benefits of Kadcyla over Herceptin for HER2-positive breast cancer with a high risk of recurrence. Read more…